Results 191 to 200 of about 5,283,585 (380)
Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceGenome sequence of the Brown Norway rat yields insights into mammalian evolution
Nature, 2004 R. Gibbs, G. Weinstock, M. Metzker, D. Muzny, E. Sodergren, S. Scherer, Graham Scott, David L. Steffen, K. Worley, P. Burch, Geoffrey O. Okwuonu, S. Hines, L. Lewis, Christine DeRamo, O. Delgado, S. Dugan-Rocha, George R. Miner, M. Morgan, A. Hawes, Rachel B. Gill, Celera, R. Holt, M. Adams, P. Amanatides, Holly Baden-Tillson, Mary Barnstead, Soo H. Chin, C. Evans, S. Ferriera, C. Fosler, A. Glodek, Z. Gu, Donald Jennings, C. Kraft, T. Nguyen, C. Pfannkoch, Cynthia D. Sitter, G. Sutton, J. Venter, T. Woodage, Douglas R. Smith, H. Lee, E. Gustafson, P. Cahill, A. Kana, L. Doucette-Stamm, Keith G Weinstock, K. Fechtel, R. Weiss, D. Dunn, E. Green, R. Blakesley, G. Bouffard, P. D. de Jong, K. Osoegawa, B. Zhu, M. Marra, J. Schein, I. Bosdet, C. Fjell, Steven P. Jones, M. Krzywinski, Carrie A. Mathewson, A. Siddiqui, N. Wye, J. McPherson, Shaying Zhao, C. Fraser, Jyoti Shetty, S. Shatsman, Keita Geer, Yixin Chen, Sofyia Abramzon, W. Nierman, P. Havlak, Rui Chen, K. Durbin, Amy Egan, Yanru Ren, Xing-Zhi Song, Bingshan Li, Yue Liu, X. Qin, S. Cawley, A. Cooney, Lisa M. D'Souza, Kirt A. Martin, Jia Qian Wu, M. Gonzalez-Garay, Andrew R. Jackson, Ken J Kalafus, M. P. McLeod, A. Milosavljevic, D. Virk, A. Volkov, D. Wheeler, Zhengdong D. Zhang, J. Bailey, E. Eichler, Eray Tuzun, E. Birney, Emmanuel Mongin, A. Ureta-Vidal, Cara Woodwark, E. Zdobnov, P. Bork, M. Suyama, D. Torrents, Marina Alexandersson, B. Trask, Janet M. Young, Hui Huang, Huajun Wang, Heming Xing, Sue Daniels, D. Gietzen, Jeanette Schmidt, Kristian Stevens, U. Vitt, J. Wingrove, F. Camara, M. Mar Albà, J. F. Abril, R. Guigó, A. Smit, I. Dubchak, E. Rubin, O. Couronne, Alexander Poliakov, N. Hübner, D. Ganten, Claudia Goesele, O. Hummel, T. Kreitler, Young-Ae Lee, J. Monti, H. Schulz, H. Zimdahl, H. Himmelbauer, H. Lehrach, H. Jacob, Susan Bromberg, J. Gullings-Handley, M. Jensen-Seaman, A. Kwitek, Jozef Lazar, D. Pasko, P. Tonellato, S. Twigger, C. Ponting, José M Duarte, S. Rice, L. Goodstadt, S. Beatson, Richard D Emes, E. Winter, C. Webber, P. Brandt, G. Nyakatura, Margaret Adetobi, Francesca Chiaromonte, L. Elnitski, Pallavi Eswara, R. Hardison, Minmei Hou, Diana L. Kolbe, K. Makova, W. Miller, A. Nekrutenko, C. Riemer, S. Schwartz, James Taylor, Shan Yang, Yi Zhang, K. Lindpaintner, T. Andrews, M. Cáccamo, M. Clamp, Laura Clarke, V. Curwen, R. Durbin, E. Eyras, S. Searle, G. Cooper, S. Batzoglou, M. Brudno, A. Sidow, Eric A. Stone, B. Payseur, G. Bourque, C. López-Otín, X. Puente, Kushal Chakrabarti, Sourav Chatterji, Colin N. Dewey, L. Pachter, Nicolas L. Bray, Von Bing Yap, A. Caspi, G. Tesler, P. Pevzner, D. Haussler, Krishna M. Roskin, R. Baertsch, H. Clawson, T. Furey, A. Hinrichs, D. Karolchik, W. Kent, K. Rosenbloom, Heather Trumbower, M. Weirauch, D. Cooper, P. Stenson, Bin Ma, M. Brent, Manimozhiyan Arumugam, David D. Shteynberg, R. Copley, Martin S. Taylor, H. Riethman, U. Mudunuri, Jane L. Peterson, M. Guyer, A. Felsenfeld, S. Old, Stephen Mockrin, F. Collins +227 moresemanticscholar +1 more sourceCytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock +10 morewiley +1 more sourceClass IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio +13 morewiley +1 more source
